Mental Health Burden in Atopic Dermatitis: Study Identifies Key Risk Factors for Anxiety and Depression
Depression and anxiety affect as many as 1 in 4 people with AD, with pruritis, sleep disorders, education level, and comorbidities identified as independent risk factors.
Circulating Inflammatory Cells Persist in Severe Asthma Despite Biologic Therapy, Study Shows
Research from the Karolinska Institute reveals that therapies such as dupilumab and mepolizumab may not eliminate Th2 lymphocytes, raising concerns about long-term remission.
FDA Backs Shield Test for Broad Early Cancer Screening: Daily Dose
Your daily dose of the clinical news you may have missed.
Phase 2b Study of Psychedelic BPL-003 Shows Rapid, Persistent, and Significant Improvement in Treatment Resistant Depression
A single dose of BPL-003 was associated with improved MADRS scores as early as day 2 that were durable through week 8; phase 3 planning is anticipated.
Majority of Americans (8 in 10) Support Routine Childhood Vaccine Requirements, According to New Harvard Poll
As authorities record data on the largest US measles outbreak in decades, 79% of Americans support school vaccine mandates for children, an encouraging result.
Mayo Clinic AI Tool Allows Rapid, Precise Identification of 9 Types of Dementia From Single Brain Scan
The StateViewer clinical decision support system could help expand access to specialist-level insights in clinics that lack neurology expertise, according to researchers.
8 Common Myths About Chronic Back Pain Plus 8 Facts That Refute Them
Back pain is more common in the US than homeownership, but despite the prevalence, myths persist regarding origins, treatment, and prevention. Here are 8 of them.
SDOH May Affect Use of Menopausal Hormone Therapy: Daily Dose
Non-Vaccine Seasonal Flu Preventive Shows Promise in Phase 2b Clinical Trial: Cidara Therapeutics
CD388, an investigational nonvaccine antiviral, demonstrated efficacy up to 76% against influenza in a cohort of more than 5000 healthy, unvaccinated adults.
Adjuvanted Vaccine Against RSV Associated with Substantial Reduced Risk of Dementia
The adjuvanted RSV vaccine, in particular, was associated with a 29% reduction in the risk of dementia in the subsequent 18 months, a University of Oxford study found.
Moderna's mRNA-1010 Flu Vaccine Proves Superior Efficacy in Pivotal Late-Stage Trial
The vaccine showed superior relative vaccine efficacy that was 26.6% higher than a licensed standard-dose influenza vaccine, Moderna reported.
Survey Finds People with Atopic Dermatitis Want Better Symptom Relief: Daily Dose
First Patient Receives Lipocene's LPCN 1154 for Postpartum Depression in Phase 3 Clinical Trial
Lipocene anticipates the phase 3 trial data will support an NDA submission for LPCN 1154 to treat PPD in mid-2026, the company said.
GLP-1 Drug Prescribing Trends Mirror Rise in US Obesity Rates
Obesity treatment evolves as GLP-1 medication use surges 587%, while bariatric surgery rates decline significantly. A new analysis parses the trends.
10 Questions on Holiday Alcohol Habits in the US
July 4th invites celebration, typically with alcohol. Try our quiz based on a review of the holiday drinking patterns of US adults. Are answers to these 10 questions what you expect?
Alzheimer Screening in Primary Care Feasible but Rare: Daily Dose
Reconstituted ACIP Votes Yes on Clesrovimab for Infants and Flu Shot For All, But Thimerosal Has Got to Go
The new, 7-member committee was clear on its support for the mAb for infants and the essential role of vaccination against influenza but wants an alternative preservative to thimerosal.
Roflumilast Cream 0.15% Receives Strong Recommendation for Atopic Dermatitis in AAD Guideline Update
Roflumilast 0.15% is the only 1 of 4 newly evaluated branded topical therapies to receive the Academy's strong recommendation for AD management in adults.
Only Half of Patients Adherent to Antidementia Medication Regimens at 1 Year: New Meta-Analysis Results
Suboptimal adherence with antidementia drugs is associated with poorer clinical outcomes including accelerated disease progression and symptomatology.
Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial
ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.
